Navigating the Confusing Landscape of Gut Health Diagnosis and Emerging Therapies
Getting a gut diagnosis is harder than it should be. SIBO, IBS, IMO, SIFO, and dysbiosis share overlapping symptoms and are frequently confused with each other. Testing methods have real limitations. And emerging therapies like FMT are expanding but still narrowly approved. This cluster helps you understand what tests actually tell you, what they miss, and where the field is heading.
Current Consensus
- SIBO breath testing has documented sensitivity and specificity limitations, with 15 to 30 percent of people producing mainly methane rather than hydrogen.
- SIFO (small intestinal fungal overgrowth) has a 25% prevalence in patients with unexplained GI symptoms but lacks universally accepted diagnostic guidelines.
- Fecal microbiota transplant is FDA-approved for recurrent C. difficile infection, with expanding investigational use in IBD, IBS, and metabolic conditions.
- Histamine intolerance is fundamentally a GI condition involving DAO enzyme deficiency, with 3x higher SIBO prevalence in MCAS patients.
- The TrioSmart 3-gas breath test represents an advance over 2-gas testing by capturing hydrogen sulfide, which older tests missed entirely.
Open Questions
- Whether a reliable non-invasive diagnostic for SIFO can be developed to replace endoscopic aspiration.
- The timeline for FMT approval beyond C. difficile, particularly for IBS and metabolic indications.
- Whether DAO supplementation provides clinically meaningful relief for histamine intolerance or primarily addresses symptoms.
- How to standardize SIBO breath test interpretation across clinical settings.
- Whether artificial sweetener effects on the small bowel microbiome are clinically significant at typical consumption levels.
Articles on Diagnosis, Testing, and What's Next and SIBO
Each article includes cited sources, a medical review placeholder, and a clear distinction between what is established and what is still being studied.
What Artificial Sweeteners Actually Do to Your Small Intestine: The Cedars-Sinai Discovery
Cedars-Sinai research revealed that artificial sweeteners affect the small bowel microbiome, not just the colon. The 2025 systematic review on synthetic versus non-synthetic sweeteners, why responses vary by baseline microbiome, and what the evidence means for your gut.
Breath Tests for SIBO: What They Actually Measure, Where They Fail, and What's Coming Next
How hydrogen, methane, and hydrogen sulfide breath tests work, why their sensitivity and specificity are limited, the TrioSmart three-gas innovation, jejunal aspirate as the gold standard, and emerging diagnostic alternatives.
Fecal Microbiota Transplant in 2026: What's Approved, What's Investigational, and What's Hype
The current state of fecal microbiota transplant: FDA-approved products (Rebyota, Vowst), OpenBiome's shutdown, next-generation products like VE303, 2024 AGA guidelines, expanding research into IBD and metabolic conditions, and why DIY FMT remains dangerous.
Histamine Intolerance, MCAS, and the Gut: Separating the Science from the Supplement Sales
Histamine intolerance is fundamentally a GI condition driven by DAO enzyme deficiency. How it connects to MCAS, the 3x SIBO prevalence in MCAS patients, why the supplement market has outpaced the evidence, and what actually helps.
SIBO vs. IBS vs. IMO vs. SIFO vs. Dysbiosis: A Diagnostic Decision Tree
A clear framework for distinguishing five overlapping gut conditions. Diagnostic criteria, test options, why SIBO prevalence in IBS ranges from 4 to 78 percent, and how to work with your clinician toward an accurate diagnosis.
SIFO: The Fungal Overgrowth Condition That Mimics SIBO (And Why It's So Hard to Diagnose)
Small intestinal fungal overgrowth affects an estimated 25% of patients with unexplained GI symptoms. Why it is underdiagnosed, how Candida marketing has complicated the science, the 8x higher risk in women, and what the evidence actually supports for testing and treatment.
Medical Disclaimer: The content in this section is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your health regimen. GLP1Gut is a tracking tool, not a medical device.